Antares Pharma, Inc. (ATRS)

[hyperopia]

I guess Bob Apple got a little heat for their silence while the stock price got pushed below $4, but really? Revenue guidance range of $135 to $155 Million, after announcing that full-year 2019 revenue is expected to be at the upper end or exceeding revenue guidance of $115 to $120 million? They only estimate ~15% - 25% growth this year? I’m all for under-promising and over-delivering, but c’mon man, that is more like the worst-case scenario of Makena immediately taken off the market, zero revenue from Gx Forteo, and low growth of Xyo and Epi. I haven’t updated my model since Q3, but I’ve got $122M for 2019, and $170 for this year, and I thought that was being conservative.